WHI Follow-Up Survey Includes Tracking Of Osteoporosis Drug Uptake
NIH plans to track the uptake of osteoporosis prevention therapies among women formerly enrolled in the discontinued Prempro arm of the Women's Health Initiative study
You may also be interested in...
Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative
Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011